Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.42 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 4/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382820 | 1.00 | CES2 (0.42) | CES2CES1MAPTKMT2AGAA | |
| Methyl Alcohol SCHEMBL28268020 | 0.92 | CES2 (0.43) | CES2CES1MAPTKMT2AGAA | |
| SCHEMBL1494587 | 0.84 | GAA (0.38) | CES2CES1MAPTKMT2AGAA | |
| SCHEMBL531337 | 0.77 | CES2 (0.52) | CES2CES1CA12CA1CA2 | |
| SCHEMBL17606773 | 0.77 | CYP3A4 (0.41) | CES2CES1CA12CA1CA2 | |
| SCHEMBL30564869 | 0.77 | CYP3A4 (0.41) | CES2CES1CA12CA1CA2 | |
| SCHEMBL29364024 | 0.77 | MAPT (0.39) | CES2CES1MAPTKMT2AGAA | |
| SCHEMBL3838838 | 0.77 | MAPT (0.39) | CES2CES1MAPTKMT2AGAA | |
| SCHEMBL1043011 | 0.73 | CA12 (0.35) | CES2CES1CA12CA1CA2 | |
| SCHEMBL22165559 | 0.72 | TSHR (0.35) | CA12CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543319-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2019-09-25 | — | — | EP | claimed |
| CN-107793289-A | A kind of preparation method of 2,3,5 trifluorobromobenzene | 上海伟和生物科技有限公司 | 2018-03-13 | — | — | CN | claimed |
| US-20140120626-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-05-01 | — | — | US | claimed |
| EP-2707465-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2014-03-19 | — | — | EP | claimed |
| WO-2012153132-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-11-15 | — | — | WO | claimed |
| EP-1362860-B1 | Method for producing tetrakis (fluoraryl)borate magnesium compound | NIPPON CATALYTIC CHEM IND (JP) | 2010-09-15 | — | — | EP | claimed |
| US-7205441-B2 | Method for producing tetrakis (fluoroaryl) borate-magnesium compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2007-04-17 | — | — | US | claimed |
| US-20030216598-A1 | Method for producing tetrakis ( fluoroaryl) borate-magnesium compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1362860-A1 | Method for producing tetrakis (fluoroaryl) borate magnesium compound | Nippon Shokubai Co., Ltd. (JP) | 2003-11-19 | — | — | EP | claimed |
| EP-0667328-B1 | Process for the preparation of aromatic fluoro compounds | CLARIANT GMBH (DE) | 1998-09-16 | — | — | EP | claimed |
| US-5498807-A | Process for the preparation of aromatic fluoro compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-03-12 | — | — | US | claimed |
| EP-0667328-A1 | Process for the preparation of aromatic fluoro compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-16 | — | — | EP | claimed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0109606-B1 | PROCESS FOR THE FORMYLATION OF ARYL HALIDES | BAYER AG (DE) | 1986-01-22 | — | — | EP | disclosed |
| US-4536344-A | USING A PHOSPINE OR PHOSPHITE | BAYER AKTIENGESELLSCHAFT (DE) | 1985-08-20 | — | — | US | disclosed |
| EP-0109606-A1 | Process for the formylation of aryl halides | BAYER AG (DE) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216598-A1 | Method for producing tetrakis ( fluoroaryl) borate-magnesium compound | KRAS, MGAM, CA3 | CES2 3957/4885CES1 4605/4885MAPT 2324/4885 |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CES2 2186/4885CES1 1763/4885MAPT 3799/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CES2 4866/4885CES1 3165/4885MAPT 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.